Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome  in advanced nonsmall cell lung cancer patients

Volkan KARACAOĞLAN; Ahmet Oğuz ADA; Serdar BİLGEN; Güzide Tuğba ÇETİNKAYA; Emre SOYDAŞ; Celalettin Semih KUNAK; Sibel Meryem ALPAR; Meral GÜLHAN; Mümtaz İŞCAN

Makale detayları

Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

Yazarlar:

Volkan KARACAOĞLAN | Ahmet Oğuz ADA | Serdar BİLGEN | Güzide Tuğba ÇETİNKAYA | Emre SOYDAŞ | Celalettin Semih KUNAK | Sibel Meryem ALPAR | Meral GÜLHAN | Mümtaz İŞCAN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2017 Vol.47 Issue 2, pp.554-562

Belge Tipi:

Makale

Yayın Tarihi:

3/2017

Belge Dili:

Türkçe

Document ID (Org No.):

2000751447

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Özet:

 

Background/aim: The association between polymorphisms of xenobiotic/drug metabolizing enzymes and TP53 and response to  chemotherapy and survival of patients with nonsmall cell lung cancer (NSCLC) are limited and inconclusive. In this study, CYP2E1*5B,  CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and  survival in 137 advanced stage NSCLC patients were investigated.  Materials and methods: Genetic polymorphism analyses were determined by polymerase chain reaction (PCR) coupled with restriction  fragment length polymorphism (RFLP).  Results: The patients with TP53 Pro/Pro variant were more likely to be resistant to chemotherapy than those with Arg/Arg variants with  marginal significance (P = 0.066). We also analyzed these gene variants in combination with CYP1A1 (Ile462Val), CYP1B1 (Asn453Ser),  GSTM1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) and GSTT1 polymorphic genes that we have previously genotyped  in the same patients (Ada et al., Neoplasma, 57, 512-527, 2010). The multivariate analysis revealed that adjusted hazard ratio (HR) of  death of the combined variant genotypes of TP53 (Arg72Pro, Pro72Pro) and CYP1A1 (Ile462Val, Val462Val) increased significantly as  compared to wild-type genotypes (HR, 6.03; 95% CI, 1.39-26.04, P = 0.016).  Conclusion: These results show that combined variant genotypes of TP53 (Arg72Pro, Pro72Pro) and CYP1A1 (Ile/Val, Val/Val) are  associated with worsening of survival in NSCLC patients.

Makale detayları

Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

Yazarlar: Volkan KARACAOĞLAN | Ahmet Oğuz ADA | Serdar BİLGEN | Güzide Tuğba ÇETİNKAYA | Emre SOYDAŞ | Celalettin Semih KUNAK | Sibel Meryem ALPAR | Meral GÜLHAN | Mümtaz İŞCAN

Yayıncı: TUBITAK

Dergi: Turkish Journal of Medical Sciences 2017 Vol.47 Issue 2, pp.554-562

Belge Tipi: Makale

Yayın Tarihi: 3/2017

Belge Dili: Türkçe

Document ID (Org No.): 2000751447

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

Sayı

Yazarlar:

Volkan KARACAOĞLAN | Ahmet Oğuz ADA | Serdar BİLGEN | Güzide Tuğba ÇETİNKAYA | Emre SOYDAŞ | Celalettin Semih KUNAK | Sibel Meryem ALPAR | Meral GÜLHAN | Mümtaz İŞCAN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2017 Vol.47 Issue 2, pp.554-562

Belge Tipi:

Makale

Yayın Tarihi:

3/2017

Belge Dili:

Türkçe

Document ID (Org No.):

2000751447

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144